Skip to main content
    S

    Silence Therapeutics PLC (SLN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $19.80
    +0.00 (+0.00%)

    Market Cap: $1.23B

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Silence Therapeutics PLC (SLN) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Silence Therapeutics (SLN) trades at 882.5x sales and 5.1x book value. Its P/S of 882.5x is above its 5-year median of 7.5x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/EN/A
    Price to sales882.5x
    Price to book5.1x
    PEGN/A
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/S882.5x7.5xN/A
    P/B5.1x3.2xN/A
    Medians of month-end values through Oct 2026: 54 to 60 months (5-year).

    Valuation History

    Over the 6 year ends shown, its P/S ranged from 2.0x in 2024 to 104.2x in 2025. 2025 was the highest of those years.

    Year endPriceP/SP/B
    2025$6.08104.2x1.1x
    2024$6.882.0x0.8x
    2023$17.376.7x8.2x
    2022$15.257.5x6.8x
    2021$23.8941.7x61.5x
    2020$22.0085.6x51.3x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    P/E history is shown only for companies that report in US dollars.

    Frequently Asked Questions About SLN

    What is SLN's price to sales ratio?

    Silence Therapeutics has a price to sales ratio of 882.5x.